JP6588893B2 - 卵巣がんの自己抗体バイオマーカー - Google Patents

卵巣がんの自己抗体バイオマーカー Download PDF

Info

Publication number
JP6588893B2
JP6588893B2 JP2016515521A JP2016515521A JP6588893B2 JP 6588893 B2 JP6588893 B2 JP 6588893B2 JP 2016515521 A JP2016515521 A JP 2016515521A JP 2016515521 A JP2016515521 A JP 2016515521A JP 6588893 B2 JP6588893 B2 JP 6588893B2
Authority
JP
Japan
Prior art keywords
ovarian cancer
autoantibodies
autoantibody
subject
anxa1
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2016515521A
Other languages
English (en)
Japanese (ja)
Other versions
JP2016536568A (ja
JP2016536568A5 (enExample
Inventor
ホフマン ピーター
ホフマン ピーター
オーラー マーティン
オーラー マーティン
マーティン カリーナ
マーティン カリーナ
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Innovation and Commercial Partners Pty Ltd
Original Assignee
Adelaide Research and Innovation Pty Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from AU2013903595A external-priority patent/AU2013903595A0/en
Application filed by Adelaide Research and Innovation Pty Ltd filed Critical Adelaide Research and Innovation Pty Ltd
Publication of JP2016536568A publication Critical patent/JP2016536568A/ja
Publication of JP2016536568A5 publication Critical patent/JP2016536568A5/ja
Application granted granted Critical
Publication of JP6588893B2 publication Critical patent/JP6588893B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57407—Specifically defined cancers
    • G01N33/57449—Specifically defined cancers of ovaries
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/3069—Reproductive system, e.g. ovaria, uterus, testes, prostate
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/564—Immunoassay; Biospecific binding assay; Materials therefor for pre-existing immune complex or autoimmune disease, i.e. systemic lupus erythematosus, rheumatoid arthritis, multiple sclerosis, rheumatoid factors or complement components C1-C9
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6854—Immunoglobulins
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Hematology (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • Biochemistry (AREA)
  • Cell Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Analytical Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Oncology (AREA)
  • Hospice & Palliative Care (AREA)
  • Rheumatology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Pregnancy & Childbirth (AREA)
  • Reproductive Health (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Rehabilitation Therapy (AREA)
  • Peptides Or Proteins (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
JP2016515521A 2013-09-18 2014-09-18 卵巣がんの自己抗体バイオマーカー Active JP6588893B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
AU2013903595 2013-09-18
AU2013903595A AU2013903595A0 (en) 2013-09-18 Autoantibody biomarkers of ovarian cancer
PCT/AU2014/000925 WO2015039175A1 (en) 2013-09-18 2014-09-18 Autoantibody biomarkers of ovarian cancer

Publications (3)

Publication Number Publication Date
JP2016536568A JP2016536568A (ja) 2016-11-24
JP2016536568A5 JP2016536568A5 (enExample) 2017-10-26
JP6588893B2 true JP6588893B2 (ja) 2019-10-09

Family

ID=52687999

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2016515521A Active JP6588893B2 (ja) 2013-09-18 2014-09-18 卵巣がんの自己抗体バイオマーカー

Country Status (7)

Country Link
US (3) US20160291025A1 (enExample)
EP (1) EP3047277B1 (enExample)
JP (1) JP6588893B2 (enExample)
CN (1) CN105745543B (enExample)
AU (1) AU2014324080B2 (enExample)
CA (1) CA2924600A1 (enExample)
WO (1) WO2015039175A1 (enExample)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN107056888A (zh) * 2017-03-01 2017-08-18 中山大学肿瘤防治中心 Atp1a1靶向多肽及应用
CN109116024B (zh) * 2018-06-14 2021-04-23 郑州大学第一附属医院 一种肺癌标志物抗-actr3自身抗体及其应用
GB201813137D0 (en) 2018-08-10 2018-09-26 Medannex Ltd Cancer treatment with an antibody
CN109182260A (zh) * 2018-09-11 2019-01-11 邵勇 一种体外培养胎膜间充质干细胞的方法
CN109480771B (zh) * 2018-10-17 2021-09-07 江西惠肽生物科技有限公司 一种卵巢肿块良恶的确定方法及确定装置
CN113785199B (zh) * 2019-03-01 2024-02-09 先进标志物探索公司 用于诊断结肠直肠癌和/或其癌前阶段的蛋白质特征
AU2020368546A1 (en) * 2019-10-16 2022-05-26 Icahn School Of Medicine At Mount Sinai Systems and methods for detecting a disease condition
US12152280B2 (en) 2021-09-20 2024-11-26 Droplet Biosciences, Inc. Drain fluid for diagnostics

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1161262B1 (en) * 1999-03-15 2008-05-21 University of Maryland, Baltimore SURFACE LOCALIZED COLLIGIN/HsP47 IN CARCINOMA CELLS
US6645465B2 (en) * 1999-08-06 2003-11-11 Michigan, University Of The Regents Annexin proteins and autoantibodies as serum markers for cancer
US20020037286A1 (en) * 2000-04-03 2002-03-28 Matthias Krause Methods for altering T cell and macrophage activation
US8614169B2 (en) * 2001-12-04 2013-12-24 Wayne State University Neoepitope detection of disease using protein arrays
EP1540010B8 (en) * 2002-08-06 2010-07-14 The Johns Hopkins University Use of biomarkers for detecting ovarian cancer
CN101268367A (zh) * 2005-06-24 2008-09-17 赛弗吉生物系统公司 卵巢癌的生物标记
AU2007211085A1 (en) * 2006-01-27 2007-08-09 Tripath Imaging, Inc. Methods for identifying patients with an increased likelihood of having ovarian cancer and compositions therefor
AU2007297310B2 (en) 2006-09-13 2013-11-07 Oncimmune Limited Improved immunoassay methods
WO2008115710A2 (en) * 2007-03-07 2008-09-25 The Johns Hopkins University Biomarkers for cancer
JP5265140B2 (ja) * 2007-06-14 2013-08-14 学校法人日本医科大学 卵巣癌の検出方法及び検出用キット
EP2637020A3 (en) * 2007-06-29 2014-01-08 Correlogic Systems Inc. Predictive markers for ovarian cancer
RU2571687C2 (ru) * 2007-11-13 2015-12-20 Феникс Байотекнолоджи Инк. Набор для определения вероятности терапевтического ответа на противораковую химиотерапию сердечным гликозидом
EP2277049A4 (en) * 2008-05-09 2012-05-30 Univ Duke AUTOANTIKÖRPER FOR THE PROOF AND THE TREATMENT OF CANCER
US20120046181A1 (en) * 2008-12-19 2012-02-23 Chu Nantes Biomarkers for the Diagnosis of Renal Allograft and Kidney Status
US20120004289A1 (en) * 2009-03-06 2012-01-05 The Johns Hopkins University Annexin a11 and associated genes as biomarkers for cancer
CN101762699A (zh) * 2009-06-24 2010-06-30 北京科美东雅生物技术有限公司 一种定量检测血液中肿瘤相关抗原125的磁性免疫层析试纸条及制备方法
US20120277326A1 (en) 2009-11-20 2012-11-01 Taylor Douglas D Biomarkers of cancer
JP2011257147A (ja) * 2010-06-04 2011-12-22 Nitto Boseki Co Ltd データ収集方法、キット及び腫瘍マーカー
WO2013112801A1 (en) * 2012-01-26 2013-08-01 Ibc Pharmaceuticals, Inc. Targeting interferon-lambda with antibodies potently enhances anti-tumor and anti-viral activities
CN102590531A (zh) * 2012-03-24 2012-07-18 广西壮族自治区肿瘤防治研究所 卵巢癌相关抗原自身抗体谱液相芯片检测试剂盒及其制备方法
JP5574348B2 (ja) * 2012-05-31 2014-08-20 国立大学法人 千葉大学 肺サルコイドーシスおよび眼サルコイドーシスの検出マーカー及び検出キット
US20140179808A1 (en) * 2012-10-23 2014-06-26 Bio-Rad Laboratories, Inc. Detection of Ovarian Carcinoma by Assay for Autoantibodies to Multiple Antigens
EP2951592A4 (en) 2013-01-31 2017-01-04 Arizona Board of Regents, a Body Corporate of the State of Arizona acting for and on behalf of Arizona State University Autoantibody signature for the early detection of ovarian cancer

Also Published As

Publication number Publication date
US20220365088A1 (en) 2022-11-17
WO2015039175A1 (en) 2015-03-26
US12287337B2 (en) 2025-04-29
CN105745543A (zh) 2016-07-06
US20160291025A1 (en) 2016-10-06
JP2016536568A (ja) 2016-11-24
AU2014324080B2 (en) 2020-07-23
EP3047277A1 (en) 2016-07-27
US20190219584A1 (en) 2019-07-18
EP3047277A4 (en) 2017-05-10
CA2924600A1 (en) 2015-03-26
AU2014324080A1 (en) 2016-04-14
CN105745543B (zh) 2018-02-02
EP3047277B1 (en) 2018-11-21
US11371993B2 (en) 2022-06-28

Similar Documents

Publication Publication Date Title
JP6588893B2 (ja) 卵巣がんの自己抗体バイオマーカー
JP6636016B2 (ja) 抗ｂ７−ｈ３抗体及びその診断用途
JP6666905B2 (ja) Ｐｄ−ｌ１抗体及びその使用
ES2745014T3 (es) Proteína
KR20150119164A (ko) Dll3 결합 시약을 포함하는 암에 대한 치료적 및 진단적 타겟
JP2011509079A (ja) エフリンａ型受容体１０タンパク質
CN104755496A (zh) 作为癌症治疗和诊断靶标的ly75
US8420091B2 (en) Matriptase protein and uses thereof
JPWO2009091023A1 (ja) 腎癌の診断又は検出のための組成物及び方法
KR20170137848A (ko) 폐암을 치료하는 방법
TWI667479B (zh) 乳癌生物標記
CA3106191A1 (en) Methods for differentiating benign prostatic hyperplasia from prostate cancer
JP2012511894A (ja) Ｐｔａ０７２タンパク質
US20130323253A1 (en) Xyxin fragment biomarker for diagnosis of colon cancer
JP2011522872A (ja) エフリンａ型受容体７タンパク質
US20120058131A1 (en) Pta089 protein
WO2022091793A1 (ja) 糞便由来タンパク質を用いた膵臓がんバイオマーカーの開発
WO2024172145A1 (ja) 腎細胞癌検出用バイオマーカー
US20090214540A1 (en) Protein involved in cancer
WO2020162441A1 (ja) 肉芽腫性疾患バイオマーカー

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20170912

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20170912

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20180523

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20180529

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20180821

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20181128

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20190507

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20190726

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20190820

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20190913

R150 Certificate of patent or registration of utility model

Ref document number: 6588893

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250